Yahoo
NasdaqGS - Delayed Quote USD

LENZ Therapeutics, Inc. (LENZ)

3.4900 +0.2800 (+8.72%)
At close: 4:00:01 PM EDT
Trade LENZ on Coinbase
LENZ Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for LENZ
  • Previous Close 3.2100
  • Open 3.0000
  • Bid 3.2300 x 200
  • Ask 3.5500 x 1700
  • Day's Range 3.0000 - 3.5800
  • 52 Week Range 3.0000 - 32.1300
  • Volume 5,985,624
  • Avg. Volume 735,148
  • Market Cap (intraday) 109.657M
  • Beta (5Y Monthly) 1.73
  • PE Ratio (TTM) --
  • EPS (TTM) -4.1300
  • Earnings Date Oct 29, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 20.00
  • Motley Fool Rating Bullish

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

www.lenz-tx.com

152

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LENZ
78.19%
S&P 500 (^GSPC)
12.78%

1-Year Return

LENZ
88.61%
S&P 500 (^GSPC)
12.04%

3-Year Return

LENZ
55.43%
S&P 500 (^GSPC)
87.51%

5-Year Return

LENZ
91.78%
S&P 500 (^GSPC)
67.64%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 3.38M
Earnings -30.97M
Profit Margin -915.16%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-40M
-30M
-20M
-10M
0
-2000.0%
-1500.0%
-1000.0%

Analyst Insights

View More

Analyst Price Targets

5.00
20.00 Average
3.4900 Current
50.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/29/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 50 -> 45

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -37.36%

  • Return on Equity (ttm)

    -59.21%

  • Revenue (ttm)

    21.48M

  • Net Income Avi to Common (ttm)

    -126M

  • Diluted EPS (ttm)

    -4.1300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    220M

  • Total Debt/Equity (mrq)

    0.26%

  • Levered Free Cash Flow (ttm)

    -71.25M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: